What it is
Beta-amyloid comes from breakdown of a larger amyloid precursor protein and can collect between neurons as plaques in Alzheimer disease.[1]
Why it matters
Anti-amyloid antibodies target amyloid biology and have been approved for certain early Alzheimer disease contexts.[2,3]
What it affects
- Confirmed amyloid pathology is part of the treatment population described in FDA donanemab approval information.[2]